share_log

Avalo Therapeutics | SC 13G: Statement of acquisition of beneficial ownership by individuals-Emerald Bioventures, LLC(5.6%),Timothy Opler(5.6%)

Avalo Therapeutics | SC 13G: Statement of acquisition of beneficial ownership by individuals-Emerald Bioventures, LLC(5.6%),Timothy Opler(5.6%)

Avalo Therapeutics | SC 13G：超过5%持股股东披露文件-Emerald Bioventures, LLC(5.6%),Timothy Opler(5.6%)
美股sec公告 ·  04/23 15:00
Moomoo AI 已提取核心信息
On March 27, 2024, Avalo Therapeutics, Inc. experienced a significant event when Emerald Bioventures, LLC and its managing member Timothy Opler filed a Schedule 13G with the SEC, indicating a 5.6% ownership in Avalo Therapeutics' common stock. This filing was required due to the acquisition of 58,346 shares of Avalo Therapeutics' common stock by Emerald Bioventures, LLC as a result of a merger. The merger involved Avalo Therapeutics, Project Athens Merger Sub, Inc., Second Project Athens Merger Sub, LLC, and AlmataBio, Inc., with the latter two entities merging into wholly owned subsidiaries of Avalo Therapeutics. The shares were acquired on the same day as the merger, and the ownership percentage is based on 1,034,130 shares of common stock outstanding as of that date. The Schedule 13G filing, made under Rule 13d-1(c), indicates that neither Emerald Bioventures, LLC nor Timothy Opler has sole voting or dispositive power over the shares, but they share both voting and dispositive power. The filing asserts that the shares were not acquired for the purpose of changing or influencing the control of Avalo Therapeutics.
On March 27, 2024, Avalo Therapeutics, Inc. experienced a significant event when Emerald Bioventures, LLC and its managing member Timothy Opler filed a Schedule 13G with the SEC, indicating a 5.6% ownership in Avalo Therapeutics' common stock. This filing was required due to the acquisition of 58,346 shares of Avalo Therapeutics' common stock by Emerald Bioventures, LLC as a result of a merger. The merger involved Avalo Therapeutics, Project Athens Merger Sub, Inc., Second Project Athens Merger Sub, LLC, and AlmataBio, Inc., with the latter two entities merging into wholly owned subsidiaries of Avalo Therapeutics. The shares were acquired on the same day as the merger, and the ownership percentage is based on 1,034,130 shares of common stock outstanding as of that date. The Schedule 13G filing, made under Rule 13d-1(c), indicates that neither Emerald Bioventures, LLC nor Timothy Opler has sole voting or dispositive power over the shares, but they share both voting and dispositive power. The filing asserts that the shares were not acquired for the purpose of changing or influencing the control of Avalo Therapeutics.
2024年3月27日，Avalo Therapeutics, Inc.经历了一起重大事件，当时Emerald Bioventures, LLC及其管理成员蒂莫西·奥勒向美国证券交易委员会提交了附表13G，表示拥有Avalo Therapeutics普通股的5.6％的所有权。之所以需要提交这份文件，是因为合并后，Emerald Bioventures, LLC收购了Avalo Therapeutics的58,346股普通股。合并涉及Avalo Therapeutics、Project Athens Merger Sub, Inc.、雅典第二项目合并子公司和AlmataBio, Inc.，后两家实...展开全部
2024年3月27日，Avalo Therapeutics, Inc.经历了一起重大事件，当时Emerald Bioventures, LLC及其管理成员蒂莫西·奥勒向美国证券交易委员会提交了附表13G，表示拥有Avalo Therapeutics普通股的5.6％的所有权。之所以需要提交这份文件，是因为合并后，Emerald Bioventures, LLC收购了Avalo Therapeutics的58,346股普通股。合并涉及Avalo Therapeutics、Project Athens Merger Sub, Inc.、雅典第二项目合并子公司和AlmataBio, Inc.，后两家实体合并为Avalo Therapeutics的全资子公司。这些股票是在合并当天收购的，所有权百分比基于截至该日已发行的1,034,130股普通股。根据第13d-1（c）条提交的附表13G文件表明，Emerald Bioventures, LLC和Timothy Opler对股票都没有唯一的投票权或处置权，但它们共享投票权和处置权。该文件称，收购这些股份不是为了改变或影响Avalo Therapeutics的控制权。

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息